





ER+ HER2- patients

ER+ HER2+ patients



A





B





C



D



E



Supplementary figure 2.

Distribution of A. $\log(\text{Ki67}_{\text{Baseline}} + 0.1)$ for all patients, B. $\log(\text{Ki67}_{2\text{week}} + 0.1)$ in patients allocated control, C. log fold change Ki67 in patients allocated control, D. $\log(\text{Ki67}_{2\text{week}} + 0.1)$ in patients allocated AI and E. log fold change Ki67 in patients allocated AI. Presented separately for HER2- and HER2+ patients.